RE:RE:RE:RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda January 17, 2024 - Roche/Genentech reported positive Phase III data for its anti-TIGIT immunotherapy at this week’s American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
In patients with esophageal squamous cell carcinoma (ESCC), tiragolumab improved progression free survival (PFS) and overall survival when combined with Tecentriq and chemotherapy versus chemo alone. SKYSCRAPER-08 enrolled 461 ESCC patients in Asian countries. Median survival in the treatment arm was 15.7 months, compared to 11.1 months in the control arm. PFS was 6.2 months versus 5.4 months in the anti-TIGIT arm compared to chemo and placebo.
Another trial of the treatment did not show any benefit to PFS in patients with non-small cell lung cancer (NSCLC). Last year, after an accidental data drop, the company announced tiragolumab also failed to improve overall survival for locally advanced or metastatic NSCLC. SKYSCRAPER-08 is one of seven Phase III trials for tiragolumab.
https://www.biospace.com/article/roche-reports-phase-iii-tigit-win-at-asco-gastro-cancer-meeting-/